TY - JOUR
T1 - CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes
AU - Lim, Colin K.W.
AU - McCallister, Tristan X.
AU - Saporito-Magriña, Christian
AU - McPheron, Garrett D.
AU - Krishnan, Ramya
AU - Zeballos C, M. Alejandra
AU - Powell, Jackson E.
AU - Clark, Lindsay V.
AU - Perez-Pinera, Pablo
AU - Gaj, Thomas
N1 - We thank Richard Chen for helpful discussion. This work was supported by the CHDI Foundation ( A-16129 ). Additional support for this work came from the National Institutes of Health ( 1U01NS122102-01A1 , 1R01NS123556-01A1 , and 5R01GM141296 ); the Muscular Dystrophy Association ( MDA602798 ); and the Judith and Jean Pape Adams Foundation . M.A.Z. was supported by the NIH / NIBIB ( T32EB019944 ), the Mavis Future Faculty Fellows Program , and a University of Illinois Aspire Fellowship.
PY - 2022/12/7
Y1 - 2022/12/7
N2 - CRISPR technology has demonstrated broad utility for controlling target gene expression; however, there remains a need for strategies capable of modulating expression via the precise editing of non-coding regulatory elements. Here, we demonstrate that CRISPR base editors, a class of gene-modifying proteins capable of creating single-base substitutions in DNA, can be used to perturb gene expression via their targeted mutagenesis of cis-acting sequences. Using the promoter region of the human huntingtin (HTT) gene as an initial target, we show that editing of the binding site for the transcription factor NF-κB led to a marked reduction in HTT gene expression in base-edited cell populations. We found that these gene perturbations were persistent and specific, as a transcriptome-wide RNA analysis revealed minimal off-target effects resulting from the action of the base editor protein. We further demonstrate that this base-editing platform could influence gene expression in vivo as its delivery to a mouse model of Huntington's disease led to a potent decrease in HTT mRNA in striatal neurons. Finally, to illustrate the applicability of this concept, we target the amyloid precursor protein, showing that multiplex editing of its promoter region significantly perturbed its expression. These findings demonstrate the potential for base editors to regulate target gene expression.
AB - CRISPR technology has demonstrated broad utility for controlling target gene expression; however, there remains a need for strategies capable of modulating expression via the precise editing of non-coding regulatory elements. Here, we demonstrate that CRISPR base editors, a class of gene-modifying proteins capable of creating single-base substitutions in DNA, can be used to perturb gene expression via their targeted mutagenesis of cis-acting sequences. Using the promoter region of the human huntingtin (HTT) gene as an initial target, we show that editing of the binding site for the transcription factor NF-κB led to a marked reduction in HTT gene expression in base-edited cell populations. We found that these gene perturbations were persistent and specific, as a transcriptome-wide RNA analysis revealed minimal off-target effects resulting from the action of the base editor protein. We further demonstrate that this base-editing platform could influence gene expression in vivo as its delivery to a mouse model of Huntington's disease led to a potent decrease in HTT mRNA in striatal neurons. Finally, to illustrate the applicability of this concept, we target the amyloid precursor protein, showing that multiplex editing of its promoter region significantly perturbed its expression. These findings demonstrate the potential for base editors to regulate target gene expression.
KW - AAV
KW - CRISPR
KW - base editing
KW - cis-regulatory elements
KW - gene regulation
UR - http://www.scopus.com/inward/record.url?scp=85136674633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136674633&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2022.08.008
DO - 10.1016/j.ymthe.2022.08.008
M3 - Article
C2 - 35965414
AN - SCOPUS:85136674633
SN - 1525-0016
VL - 30
SP - 3619
EP - 3631
JO - Molecular Therapy
JF - Molecular Therapy
IS - 12
ER -